Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
ELOS's Cash-to-Debt is ranked higher than
96% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. ELOS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ELOS' s Cash-to-Debt Range Over the Past 10 Years
Min: 15.11  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.75
ELOS's Equity-to-Asset is ranked higher than
73% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. ELOS: 0.75 )
Ranked among companies with meaningful Equity-to-Asset only.
ELOS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.75 Max: 0.86
Current: 0.75
0.5
0.86
Interest Coverage 17.69
ELOS's Interest Coverage is ranked lower than
66% of the 241 Companies
in the Global Medical Devices industry.

( Industry Median: 77.33 vs. ELOS: 17.69 )
Ranked among companies with meaningful Interest Coverage only.
ELOS' s Interest Coverage Range Over the Past 10 Years
Min: 14.74  Med: 126.63 Max: No Debt
Current: 17.69
Piotroski F-Score: 8
Altman Z-Score: 5.07
Beneish M-Score: -2.53
WACC vs ROIC
9.05%
0.36%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 1.09
ELOS's Operating Margin % is ranked lower than
54% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.84 vs. ELOS: 1.09 )
Ranked among companies with meaningful Operating Margin % only.
ELOS' s Operating Margin % Range Over the Past 10 Years
Min: -43.96  Med: -2.35 Max: 22
Current: 1.09
-43.96
22
Net Margin % 0.06
ELOS's Net Margin % is ranked lower than
55% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. ELOS: 0.06 )
Ranked among companies with meaningful Net Margin % only.
ELOS' s Net Margin % Range Over the Past 10 Years
Min: -43.1  Med: -1.27 Max: 22.16
Current: 0.06
-43.1
22.16
ROE % 0.09
ELOS's ROE % is ranked lower than
56% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. ELOS: 0.09 )
Ranked among companies with meaningful ROE % only.
ELOS' s ROE % Range Over the Past 10 Years
Min: -19.9  Med: -1.43 Max: 14.7
Current: 0.09
-19.9
14.7
ROA % 0.07
ELOS's ROA % is ranked lower than
51% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.21 vs. ELOS: 0.07 )
Ranked among companies with meaningful ROA % only.
ELOS' s ROA % Range Over the Past 10 Years
Min: -14.56  Med: -1.06 Max: 12.64
Current: 0.07
-14.56
12.64
ROC (Joel Greenblatt) % 6.75
ELOS's ROC (Joel Greenblatt) % is ranked higher than
53% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 4.32 vs. ELOS: 6.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ELOS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -397.3  Med: -14.81 Max: 133.88
Current: 6.75
-397.3
133.88
3-Year Revenue Growth Rate 6.30
ELOS's 3-Year Revenue Growth Rate is ranked higher than
56% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. ELOS: 6.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ELOS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 9.3 Max: 190.6
Current: 6.3
0
190.6
3-Year EBITDA Growth Rate 41.40
ELOS's 3-Year EBITDA Growth Rate is ranked higher than
87% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 5.60 vs. ELOS: 41.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ELOS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -46.2  Med: 14.95 Max: 99.5
Current: 41.4
-46.2
99.5
3-Year EPS without NRI Growth Rate -37.00
ELOS's 3-Year EPS without NRI Growth Rate is ranked lower than
88% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. ELOS: -37.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ELOS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -64  Med: -18.8 Max: 98.2
Current: -37
-64
98.2
GuruFocus has detected 3 Warning Signs with Syneron Medical Ltd $ELOS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ELOS's 10-Y Financials

Financials (Next Earnings Date: 2017-05-22 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ELOS Guru Trades in Q1 2016

Charles Brandes 2,509,446 sh (+43.75%)
Chuck Royce 713,159 sh (+7.54%)
Jim Simons 928,806 sh (+3.13%)
Mario Gabelli 24,000 sh (unchged)
Ronald Muhlenkamp Sold Out
» More
Q2 2016

ELOS Guru Trades in Q2 2016

Chuck Royce 788,159 sh (+10.52%)
Charles Brandes 2,723,535 sh (+8.53%)
Jim Simons 965,106 sh (+3.91%)
Mario Gabelli 24,000 sh (unchged)
» More
Q3 2016

ELOS Guru Trades in Q3 2016

Charles Brandes 3,414,913 sh (+25.39%)
Jim Simons 1,021,606 sh (+5.85%)
Mario Gabelli 24,000 sh (unchged)
Chuck Royce 420,659 sh (-46.63%)
» More
Q4 2016

ELOS Guru Trades in Q4 2016

Jim Simons 1,141,441 sh (+11.73%)
Charles Brandes 3,660,613 sh (+7.19%)
Mario Gabelli 24,000 sh (unchged)
Chuck Royce 69,200 sh (-83.55%)
» More
» Details

Insider Trades

Latest Guru Trades with ELOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices  
Compare:NYSE:IVC, NAS:EXAC, NAS:ARAY, NAS:AXGN, NAS:TCMD, NAS:CUTR, NAS:VRAY, NAS:XENT, OTCPK:NMRD, AMEX:CVRS, NAS:RTIX, OTCPK:IPDQF, NYSE:CRY, NAS:OBLN, OTCPK:MZRTF, NAS:PAVM, NAS:IRIX, NAS:ACRX, OTCPK:SBMAF, NAS:NVCN » details
Traded in other countries:FGD.Germany,
Syneron Medical Ltd designs, develops & markets aesthetic medical products based on its proprietary technologies. Its offers Skin Rejuvenation, Age Spots, Cellulite Reduction, Acne, & Hair Removal among others.

Syneron Medical Ltd., was incorporated in the State of Israel in July 2000. The Company completed its initial public offering of ordinary shares in August 2004. It designs, develops and markets aesthetic medical products based on its various technologies including its proprietary Electro-Optical Synergy, or ELOS, technology, which uses the synergy between electrical energy, including radiofrequency or RF energy, and optical energy to provide effective, safe and affordable aesthetic medical treatments. The Company's products, which it sells mainly to physicians and other practitioners, target non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin and laser-assisted lipolysis and topical skin brightening products. ELOS provides performance advantages over existing technologies that rely solely on optical energy. The Company's proprietary ELOS technology, which combines optical and electrical energy, enhances the user's ability to accurately target the tissue to be treated and enables real-time measurement of skin temperature, resulting in increased patient safety and comfort and improved treatment results. Its patent portfolio (including patents held by subsidiaries) consisted of 140 issued U.S. patents.The Company's trademarks include Syneron, Elos, Candela, Ultrashape, Litetouch, VelaShape, VelaSmooth, Sublative, eTwo, eMax, ePRIME, eLase, elosPlus, Elure, Motif, Co2re, eMatrix, Matrix IR, Matrix RF, Refirme. It competes with large pharmaceutical companies that have entered the aesthetic device market, such as Valeant Pharmaceuticals International Inc. (which acquired Solta Medical Inc. in 2014), Merz Pharma Group (which acquired Ulthera, Inc. in 2014) and Actevis PLC (which acquired Allergan, Inc. in 2014). Its products compete against conventional non-light-based treatments, including Botox (neurotoxins) and hyaluronic acid injections, face lifts, sclerotherapy, electrolysis, liposuction, chemical peels and microdermabrasion. The Company's products are medical devices and cosmetics subject to extensive and rigorous regulation by the FDA, as well as other U.S. and foreign regulatory bodies.

Ratios

vs
industry
vs
history
PE Ratio 527.50
ELOS's PE Ratio is ranked lower than
98% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 26.64 vs. ELOS: 527.50 )
Ranked among companies with meaningful PE Ratio only.
ELOS' s PE Ratio Range Over the Past 10 Years
Min: 6.8  Med: 18.26 Max: 1035
Current: 527.5
6.8
1035
PE Ratio without NRI 527.50
ELOS's PE Ratio without NRI is ranked lower than
98% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 28.00 vs. ELOS: 527.50 )
Ranked among companies with meaningful PE Ratio without NRI only.
ELOS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.8  Med: 18.26 Max: 1242
Current: 527.5
6.8
1242
PB Ratio 1.76
ELOS's PB Ratio is ranked higher than
72% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 3.37 vs. ELOS: 1.76 )
Ranked among companies with meaningful PB Ratio only.
ELOS' s PB Ratio Range Over the Past 10 Years
Min: 0.58  Med: 1.58 Max: 5.16
Current: 1.76
0.58
5.16
PS Ratio 1.24
ELOS's PS Ratio is ranked higher than
75% of the 329 Companies
in the Global Medical Devices industry.

( Industry Median: 3.34 vs. ELOS: 1.24 )
Ranked among companies with meaningful PS Ratio only.
ELOS' s PS Ratio Range Over the Past 10 Years
Min: 0.77  Med: 1.7 Max: 8.93
Current: 1.24
0.77
8.93
Price-to-Free-Cash-Flow 83.07
ELOS's Price-to-Free-Cash-Flow is ranked lower than
90% of the 124 Companies
in the Global Medical Devices industry.

( Industry Median: 28.14 vs. ELOS: 83.07 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ELOS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.33  Med: 19.23 Max: 285.19
Current: 83.07
4.33
285.19
Price-to-Operating-Cash-Flow 44.52
ELOS's Price-to-Operating-Cash-Flow is ranked lower than
83% of the 155 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. ELOS: 44.52 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ELOS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.16  Med: 18.74 Max: 773.57
Current: 44.52
4.16
773.57
EV-to-EBIT 71.53
ELOS's EV-to-EBIT is ranked lower than
89% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 22.27 vs. ELOS: 71.53 )
Ranked among companies with meaningful EV-to-EBIT only.
ELOS' s EV-to-EBIT Range Over the Past 10 Years
Min: -119.6  Med: -3.7 Max: 691.6
Current: 71.53
-119.6
691.6
EV-to-EBITDA 23.83
ELOS's EV-to-EBITDA is ranked lower than
69% of the 238 Companies
in the Global Medical Devices industry.

( Industry Median: 16.71 vs. ELOS: 23.83 )
Ranked among companies with meaningful EV-to-EBITDA only.
ELOS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -294.8  Med: 13 Max: 173.3
Current: 23.83
-294.8
173.3
Current Ratio 2.87
ELOS's Current Ratio is ranked higher than
61% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.28 vs. ELOS: 2.87 )
Ranked among companies with meaningful Current Ratio only.
ELOS' s Current Ratio Range Over the Past 10 Years
Min: 2.4  Med: 3.18 Max: 9.16
Current: 2.87
2.4
9.16
Quick Ratio 2.14
ELOS's Quick Ratio is ranked higher than
60% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. ELOS: 2.14 )
Ranked among companies with meaningful Quick Ratio only.
ELOS' s Quick Ratio Range Over the Past 10 Years
Min: 1.9  Med: 2.77 Max: 8.89
Current: 2.14
1.9
8.89
Days Inventory 124.17
ELOS's Days Inventory is ranked higher than
51% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 124.59 vs. ELOS: 124.17 )
Ranked among companies with meaningful Days Inventory only.
ELOS' s Days Inventory Range Over the Past 10 Years
Min: 57.94  Med: 110.49 Max: 205.18
Current: 124.17
57.94
205.18
Days Sales Outstanding 70.20
ELOS's Days Sales Outstanding is ranked lower than
53% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 67.79 vs. ELOS: 70.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
ELOS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 69.22  Med: 78.41 Max: 117.09
Current: 70.2
69.22
117.09
Days Payable 58.05
ELOS's Days Payable is ranked higher than
51% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. ELOS: 58.05 )
Ranked among companies with meaningful Days Payable only.
ELOS' s Days Payable Range Over the Past 10 Years
Min: 50.87  Med: 66.08 Max: 106.72
Current: 58.05
50.87
106.72

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.80
ELOS's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. ELOS: 1.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ELOS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -70.6  Med: -6.85 Max: 1.8
Current: 1.8
-70.6
1.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 3.18
ELOS's Price-to-Net-Current-Asset-Value is ranked higher than
76% of the 240 Companies
in the Global Medical Devices industry.

( Industry Median: 6.87 vs. ELOS: 3.18 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ELOS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.14  Med: 2.53 Max: 7.79
Current: 3.18
1.14
7.79
Price-to-Tangible-Book 2.03
ELOS's Price-to-Tangible-Book is ranked higher than
74% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 4.36 vs. ELOS: 2.03 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ELOS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.97  Med: 1.86 Max: 7.55
Current: 2.03
0.97
7.55
Price-to-Intrinsic-Value-Projected-FCF 7.93
ELOS's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
90% of the 147 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. ELOS: 7.93 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ELOS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.6 Max: 43.93
Current: 7.93
0.52
43.93
Price-to-Median-PS-Value 0.73
ELOS's Price-to-Median-PS-Value is ranked higher than
75% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. ELOS: 0.73 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ELOS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.58  Med: 1.09 Max: 5.9
Current: 0.73
0.58
5.9
Price-to-Graham-Number 6.90
ELOS's Price-to-Graham-Number is ranked lower than
91% of the 146 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. ELOS: 6.90 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ELOS' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.93  Med: 2.36 Max: 9.86
Current: 6.9
0.93
9.86
Earnings Yield (Greenblatt) % 1.39
ELOS's Earnings Yield (Greenblatt) % is ranked higher than
54% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. ELOS: 1.39 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ELOS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 7.4 Max: 6887.2
Current: 1.39
0.1
6887.2

More Statistics

Revenue (TTM) (Mil) $298.1
EPS (TTM) $ 0.02
Beta0.97
Short Percentage of Float1.58%
52-Week Range $6.18 - 10.85
Shares Outstanding (Mil)35.02

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 0.43
EPS without NRI ($) 0.43
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ELOS

Headlines

Articles On GuruFocus.com
Retrophin At All-Time High Levels on RE-024 FDA-Status; Syneron Settles Legal Battle Jun 05 2015 
Why Is Seth Klarman Loading Up on Syneron Medical? Aug 29 2011 
Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
Seth Klarman More Than Doubles Holdings in Syneron Medical Jul 12 2011 
Top Seth Klarman Holding, ELOS Rockets Up 20% Feb 16 2011 
Baupost’s Seth Klarman Buys Enzon Inc., Viasat Inc., Sells Horizon Lines Inc., News Corp., PDL Bio Nov 12 2009 
Seth Klarman Buys First American Corp., Universal Compression Holdings, School Specialty Inc., Sells Aug 13 2007 
Seth Klarman Buys Home Depot Inc., InfoSpace Inc., Multimedia Games Inc., Sells Laidlaw Internationa Nov 13 2006 

More From Other Websites
Syneron Candela Announces CE Mark for CO2RE® Intima Mar 26 2017
Syneron Medical Ltd. Announces Availability of its Annual Report on Form 20-F through its Website Mar 23 2017
Syneron Candela Announces New Technology and Indications at the 2017 American Academy of Dermatology... Mar 01 2017
Syneron Medical Ltd. :ELOS-US: Earnings Analysis: Q4, 2016 By the Numbers : February 16, 2017 Feb 16 2017
Syneron Medical Reports 4Q Loss of 3 Cents a Share Feb 16 2017
Edited Transcript of ELOS earnings conference call or presentation 15-Feb-17 1:30pm GMT Feb 15 2017
Syneron Medical reports 4Q loss Feb 15 2017
Syneron Medical reports 4Q loss Feb 15 2017
Q4 2016 Syneron Medical Ltd Earnings Release - Before Market Open Feb 15 2017
Syneron Medical Reports Fourth Quarter 2016 Revenue of $82.9 Million and Full Year 2016 Revenue... Feb 15 2017
Hologic to buy Cynosure to expand into medical aesthetics Feb 14 2017
Syneron Medical to Participate in Leerink Partners 6th Annual Global Healthcare Conference Feb 13 2017
Apax Partners in talks to buy Israel's Syneron Medical -report Feb 13 2017
Apax Partners in talks to buy Israel's Syneron Medical -report Feb 13 2017
Sientra Appoints Aesthetic Industry Leader Philippe A. Schaison to Board of Directors Feb 07 2017
Syneron Medical Strengthens Senior Management Team with Appointment of Chief Human Resources Officer Jan 31 2017
Syneron Medical to Report Fourth Quarter and Full Year 2016 Financial Results on February 15, 2017 Jan 30 2017
ETFs with exposure to Syneron Medical Ltd. : January 25, 2017 Jan 25 2017
ETFs with exposure to Syneron Medical Ltd. : December 9, 2016 Dec 09 2016
Top Ranked Momentum Stocks to Buy for December 9th Dec 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)